These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22083191

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
    Chang YS, Er TK, Lu HC, Yeh KT, Chang JG.
    Clin Chim Acta; 2014 Sep 25; 436():169-75. PubMed ID: 24863805
    [Abstract] [Full Text] [Related]

  • 5. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 25; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 25; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 7. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J.
    J Clin Oncol; 2013 Feb 20; 31(6):759-65. PubMed ID: 23182985
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
    Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, Nappi O, Iaffaioli RV, Botti G, Normanno N.
    Pharmacogenomics; 2010 Aug 20; 11(8):1169-79. PubMed ID: 20712532
    [Abstract] [Full Text] [Related]

  • 10. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC, Grebe SK.
    Clin Chim Acta; 2013 Oct 21; 425():1-2. PubMed ID: 23832066
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
    Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M.
    Clin Cancer Res; 2011 Jul 15; 17(14):4901-14. PubMed ID: 21632860
    [Abstract] [Full Text] [Related]

  • 13. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
    Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S, Dandachi N, Zeillinger R, Kriegshäuser G.
    J Mol Diagn; 2009 Nov 15; 11(6):508-13. PubMed ID: 19797612
    [Abstract] [Full Text] [Related]

  • 14. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
    Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y.
    Jpn J Clin Oncol; 2011 Feb 15; 41(2):165-71. PubMed ID: 20926413
    [Abstract] [Full Text] [Related]

  • 15. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
    Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K, Japanese Society of Medical Oncology.
    Cancer Sci; 2015 Mar 15; 106(3):324-7. PubMed ID: 25800101
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles.
    Huang Q, Wang GY, Huang JF, Zhang B, Fu WL.
    Mol Cell Probes; 2010 Dec 15; 24(6):376-80. PubMed ID: 20732413
    [Abstract] [Full Text] [Related]

  • 18. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.
    Dudley J, Tseng LH, Rooper L, Harris M, Haley L, Chen G, Gocke CD, Eshleman JR, Lin MT.
    Arch Pathol Lab Med; 2015 Feb 15; 139(2):211-8. PubMed ID: 25611103
    [Abstract] [Full Text] [Related]

  • 19. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC.
    J Mol Diagn; 2012 Feb 15; 14(3):247-55. PubMed ID: 22425762
    [Abstract] [Full Text] [Related]

  • 20. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X, Wang Y, Gao N, Wang J.
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb 15; 43(2):77-82. PubMed ID: 24742565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.